Bisirna Therapeutics

BiSiRNA Therapeutics is a biotechnology company focused on developing next-generation RNA interference (RNAi) therapies to treat cancer. The company's core technology is a proprietary bi-functional siRNA (bi-siRNA) platform that combines both cleavage-dependent and cleavage-independent pathways to achieve more potent and long-lasting gene silencing. Its lead candidate, BSR-01, is a potent siRNA targeting the KRAS G12D mutation, which is a major driver in pancreatic and colorectal cancers. BiSiRNA Therapeutics maintains operations in both Suzhou, China, and the United States, positioning itself to address high-unmet-need oncological indications globally.